Background and Objective: Oral zolmitriptan is highly effective in the acute treatment of migraine. However, nausea and vomiting during attacks may limit the usefulness of oral medications.
Zolmitriptan was detectable in plasma 2 minutes after intranasal administration in 75% (18/24) of subjects receiving the 2.5mg dose and in 79% (19/24) of subjects receiving the 5mg dose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results